You are here

Prevnar 13 Prevents Community-Acquired Pneumonia in Older Adults

Pivotal trial meets primary objective in subjects aged 65 years and older (February 24)

The Community-Acquired Pneumonia Immunization Trial in Adults (CAPiTA) — a landmark study of approximately 85,000 subjects evaluating the efficacy of Prevnar 13 (pneumococcal polysaccharide conjugate vaccine [13-valent, adsorbed], Pfizer) in adults 65 years of age and older — has achieved its primary clinical objective and both secondary clinical objectives.

The study’s primary objective was to demonstrate the efficacy of Prevnar 13 against a first episode of vaccine-type community-acquired pneumonia (CAP). The CAPiTA study also met both secondary objectives, which were efficacy against a first episode of non-bacteremic/non-invasive vaccine-type CAP (VT-CAP), and against a first episode of vaccine-type invasive pneumococcal disease (IPD).

VT-CAP was defined as CAP caused by any Streptococcus pneumoniae serotype included in the vaccine. Non-bacteremic/non-invasive VT-CAP was defined as CAP in which vaccine-type S. pneumoniae caused the pneumonia but was not detected concurrently in the bloodstream or at any other normally sterile site. Vaccine-type IPD was defined as a case in which vaccine-type S. pneumoniae was present in the bloodstream or any other normally sterile site, with or without pneumonia.

The results will be presented March 12 at the 9th International Symposium on Pneumococci and Pneumococcal Diseases (ISPPD)in Hyderabad, India.

In the U.S., Prevnar 13 is approved for use in children 6 weeks through 5 years of age for active immunization for the prevention of invasive disease and otitis media caused by S. pneumoniae serotypes; in children 6 through 17 years of age for active immunization for the prevention of invasive disease caused by S. pneumoniae serotypes; and for adults 50 years of age and older for the prevention of pneumonia and invasive disease caused by S. pneumoniae serotypes.

Source: Pfizer; February 24, 2014.

Recent Headlines

Possible First Treatment Option for Rare Autoimmune Disease of the CNS
New Hematologic Biomarker Test Provides New Approach to Sepsis Triage and Diagnosis
Antibiotics, Statins, and Glucocorticoids All Show Promise
Current, Sole Therapy Not Always Successful/Suitable
Over 1.5 Million Americans Likely to have Wet AMD by 2020 
Potential For Use Against E. Coli, TB, Resistant Bacteria
More Than 32% of Patients Responded in Trial
Drug Improved or Stabilized Symptoms, Shrank Brain Lesions